Posterior reversible encephalopathy syndrome in childhood hematological/oncological diseases: Multicenter resulte
dc.contributor.author | Bilir, Özlem Arman | |
dc.contributor.author | Dikme, Gürcan | |
dc.contributor.author | Malbora, Barış | |
dc.contributor.author | Sivis, Zühal Önder | |
dc.contributor.author | Tüfekçi, Özlem | |
dc.contributor.author | Bahadır, Ayşenur | |
dc.contributor.author | Karaman, Serap | |
dc.contributor.author | Vural, Sema | |
dc.contributor.author | Bayhan, Turan | |
dc.contributor.author | Yaralı, Hüsniye Neşe | |
dc.contributor.author | Çelkan, Tülin Tiraje | |
dc.contributor.author | Özbek, Namık Yaşar | |
dc.contributor.buuauthor | Evim, Melike Sezgin | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Hematoloji ve Onkoloji Anabilim Dalı. | tr_TR |
dc.contributor.researcherid | AAH-1452-2021 | tr_TR |
dc.contributor.scopusid | 36337796600 | tr_TR |
dc.date.accessioned | 2024-01-22T07:58:14Z | |
dc.date.available | 2024-01-22T07:58:14Z | |
dc.date.issued | 2021-05 | |
dc.description.abstract | The aim of the study was to analyze the characteristics of posterior reversible encephalopathy syndrome (PRES) cases treated at 10 different institutions in our country. Fifty-eight patients diagnosed with PRES were included in this study. The data of PRES cases from 10 departments of pediatric hematology/oncology were analyzed. The mean age of the patients at the time of diagnosis of PRES was 8.95±3.66 years. Most patients (80.4%) had a primary diagnosis of acute leukemia. Patients received chemotherapy (71.4%) and/or used steroids within 14 days before the diagnosis of PRES (85.7%). Hypertension was found in 83.9% of the patients. Twenty-six patients had infections and 22 of them had febrile neutropenia. The most common electrolyte disorders were hypocalcemia, hypomagnesemia, and hypopotassemia. Six patients had tumor lysis syndrome and 4 had inappropriate antidiuretic hormone syndrome. Magnetic resonance imaging was used for diagnosis in all patients. The most commonly involved regions by magnetic resonance imaging were occipital (58%), parietal (51%), and frontal lobes (45%), respectively. Twenty-five patients required intensive care and 7 patients were intubated. In conclusion, PRES may develop during the follow-up and treatment of hematological diseases. In addition to steroid and intense combined chemotherapies, immunosuppressive agents and hypertension are also factors that may be responsible for PRES. | en_US |
dc.identifier.citation | Bilir, Ö. A. vd. (2021). "Posterior reversible encephalopathy syndrome in childhood hematological/oncological diseases: Multicenter resulte". Journal of Pediatric Hematology/Oncology, 43(4), E462-E465. | en_US |
dc.identifier.doi | https://doi.org/10.1097/MPH.0000000000001965 | |
dc.identifier.eissn | 1536-3678 | |
dc.identifier.endpage | E465 | tr_TR |
dc.identifier.issn | 1077-4114 | |
dc.identifier.issue | 4 | tr_TR |
dc.identifier.pubmed | 33060391 | tr_TR |
dc.identifier.scopus | 2-s2.0-85105548823 | tr_TR |
dc.identifier.startpage | E462 | tr_TR |
dc.identifier.uri | https://journals.lww.com/jpho-online/fulltext/2021/05000/posterior_reversible_encephalopathy_syndrome_in.10.aspx | |
dc.identifier.uri | https://hdl.handle.net/11452/39209 | |
dc.identifier.volume | 42 | tr_TR |
dc.identifier.wos | 000647760900010 | |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Lippincott Williams and Wilkins | en_US |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.collaboration | Sanayi | tr_TR |
dc.relation.journal | Journal of Pedıatrıc Hematology Oncology | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Child | en_US |
dc.subject | Pres | en_US |
dc.subject | Encephalopathy | en_US |
dc.subject | Hematologic disease | en_US |
dc.subject | Hypertension | en_US |
dc.subject | Nervous-system complications | en_US |
dc.subject | Acute lymphoblastic-leukemia | en_US |
dc.subject | Children | en_US |
dc.subject | Leukoencephalopathy | en_US |
dc.subject | Manifestations | en_US |
dc.subject | Chemotherapy | en_US |
dc.subject | Hematopoietic stem-cell | en_US |
dc.subject | Oncology | en_US |
dc.subject | Hematology | en_US |
dc.subject | Pediatrics | en_US |
dc.subject.emtree | Anticonvulsive agent | en_US |
dc.subject.emtree | Antineoplastic agent | en_US |
dc.subject.emtree | Cyclosporine | en_US |
dc.subject.emtree | Mycophenolate mofetil | en_US |
dc.subject.emtree | Steroid | en_US |
dc.subject.emtree | Acute ieukemia | en_US |
dc.subject.emtree | Acute iymphoblastic leukemia | en_US |
dc.subject.emtree | Acute myeloid leukemia | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Aplastic anemia | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Ataxia telangiectasia | en_US |
dc.subject.emtree | B cell ieukemia | en_US |
dc.subject.emtree | Burkitt ieukemia | en_US |
dc.subject.emtree | Burkitt ieukemia | en_US |
dc.subject.emtree | Burkitt iymphoma | en_US |
dc.subject.emtree | Cancer chemotherapy | en_US |
dc.subject.emtree | Cancer combination chemotherapy | en_US |
dc.subject.emtree | Cancer diagnosis | en_US |
dc.subject.emtree | Child | en_US |
dc.subject.emtree | Childhood cancer | en_US |
dc.subject.emtree | Clinical feature | en_US |
dc.subject.emtree | Congenital amegakaryocytic thrombocytopenia | en_US |
dc.subject.emtree | Disease predisposition | en_US |
dc.subject.emtree | Endotracheal intubation | en_US |
dc.subject.emtree | Epilepsy | en_US |
dc.subject.emtree | Febrile neutropenia | en_US |
dc.subject.emtree | Frontal lobe | en_US |
dc.subject.emtree | Hematologic malignancy | en_US |
dc.subject.emtree | Hematology | en_US |
dc.subject.emtree | Hemophagocytic syndrome | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Hypertension | en_US |
dc.subject.emtree | Hypocalcemia | en_US |
dc.subject.emtree | Hypokalemia | en_US |
dc.subject.emtree | Hypomagnesemia | en_US |
dc.subject.emtree | Inappropriate vasopressin secretion | en_US |
dc.subject.emtree | Infection | en_US |
dc.subject.emtree | Intensive care | en_US |
dc.subject.emtree | Leukemia | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Multicenter study (topic) | en_US |
dc.subject.emtree | Nuclear magnetic resonance imaging | en_US |
dc.subject.emtree | Occipital lobe | en_US |
dc.subject.emtree | Oncology | en_US |
dc.subject.emtree | Parietal lobe | en_US |
dc.subject.emtree | Pediatric ward | en_US |
dc.subject.emtree | Posterior reversible encephalopathy syndrome | en_US |
dc.subject.emtree | Retrospective study | en_US |
dc.subject.emtree | Risk factor | en_US |
dc.subject.emtree | T cell leukemia | en_US |
dc.subject.emtree | Thalassemia major | en_US |
dc.subject.emtree | Tumor lysis syndrome | en_US |
dc.subject.emtree | Adolescent | en_US |
dc.subject.emtree | Clinical trial | en_US |
dc.subject.emtree | Complication | en_US |
dc.subject.emtree | Diagnostic imaging | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Hematologic disease | en_US |
dc.subject.emtree | Leukemia | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Metabolic disorder | en_US |
dc.subject.emtree | Multicenter study | en_US |
dc.subject.emtree | Posterior reversible encephalopathy syndrome | en_US |
dc.subject.mesh | Adolescent | en_US |
dc.subject.mesh | Child | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Hematologic diseases | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Hypertension | en_US |
dc.subject.mesh | Leukemia | en_US |
dc.subject.mesh | Magnetic | en_US |
dc.subject.mesh | Resonance imaging | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Posterior leukoencephalopathy syndrome | en_US |
dc.subject.mesh | Water-electrolyte imbalance | en_US |
dc.subject.scopus | Posterior Reversible Encephalopathy Syndrome; Case Report; Hypertension Encephalopathy | en_US |
dc.subject.wos | Oncology | en_US |
dc.subject.wos | Hematology | en_US |
dc.subject.wos | Pediatrics | en_US |
dc.title | Posterior reversible encephalopathy syndrome in childhood hematological/oncological diseases: Multicenter resulte | en_US |
dc.type | Article | en_US |
dc.wos.quartile | Q4 | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: